Jazz Pharmaceuticals plc
JAZZ
$138.81
$2.361.73%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.53% | 8.52% | 6.95% | 1.03% | 4.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.53% | 8.52% | 6.95% | 1.03% | 4.10% |
| Cost of Revenue | 21.40% | 9.26% | 12.68% | -2.41% | -22.92% |
| Gross Profit | 6.43% | 8.43% | 6.30% | 1.31% | 7.10% |
| SG&A Expenses | 11.00% | 5.66% | -0.68% | 18.06% | 12.02% |
| Depreciation & Amortization | 4.85% | 1.66% | 2.08% | 3.97% | 10.31% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.58% | -0.62% | 3.09% | 12.98% | 10.20% |
| Operating Income | -2.55% | 50.94% | 26.52% | -43.92% | -12.06% |
| Income Before Tax | 118.13% | 101.24% | 72.15% | -105.45% | 117.92% |
| Income Tax Expenses | -75.02% | 69.19% | -26.02% | 176.15% | 66.92% |
| Earnings from Continuing Operations | 102.98% | 46.48% | 61.40% | -121.06% | 139.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 102.98% | 46.48% | 61.40% | -121.06% | 139.11% |
| EBIT | -2.55% | 50.94% | 26.52% | -43.92% | -12.06% |
| EBITDA | 0.82% | 27.02% | 14.27% | -22.14% | -4.30% |
| EPS Basic | 109.82% | 50.53% | 64.25% | -121.38% | 139.41% |
| Normalized Basic EPS | 2.11% | 106.82% | 75.18% | -68.38% | -7.87% |
| EPS Diluted | 118.51% | 59.66% | 64.28% | -122.57% | 137.25% |
| Normalized Diluted EPS | 11.90% | 127.11% | 81.82% | -63.26% | -17.25% |
| Average Basic Shares Outstanding | -3.26% | -2.69% | -1.73% | -1.51% | -0.75% |
| Average Diluted Shares Outstanding | -11.73% | -11.39% | -5.32% | -15.23% | 10.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
